Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: A TransATAC study

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 253-262

  Afentakis, Maria ^a   Dowsett, Mitch ^a   Sestak, Ivana ^b   Salter, Janine ^a   Howell, Tony ^c   Buzdar, Aman ^d   Forbes, John ^e   Cuzick, Jack ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

BAG1; Breast cancer; Distance recurrence; IHC4; TransATAC study

Indexed keywords

ANASTROZOLE; BAG1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; REGULATOR PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; BCL2-ASSOCIATED ATHANOGENE 1 PROTEIN; DNA BINDING PROTEIN; ERBB2 PROTEIN, HUMAN; NITRILE; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CELL NUCLEUS; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE MARKER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; BIOSYNTHESIS; BREAST NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84881481158     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2628-5     Document Type: Article

References (18)

1. Dowsett M, Goldhirsch A, Hayes DF, et al. (2007) International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9(6):R81
2. Cuzick J, Sestak I, Baum M, et al. (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135-1141
3. Dowsett M, Cuzick J, Wale C, et al. (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28(11):1829-1834
4. Tang SC, Beck J, Murphy S, et al. (2004) BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma. Breast Cancer Res Treat 84(3):203-213
5. Dowsett M, Allred C, Knox J, et al. (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 26(7):1059-1065
6. Cuzick J, Dowsett M, Pineda S, et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29(32):4273-4278
7. Christiansen J, Bartlett JMS, Gustavson M et al. (2012) Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. J Clin Oncol 30 (suppl: abstract 517):2977-2298
8. Paik S, Shak S, Tang G, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826
9. Townsend PA, Stephanou A, Packham G, et al. (2005) BAG-1: a multi-functional pro-survival molecule. Int J Biochem Cell Biol 37(2):251-259
10. Townsend PA, Dublin E, Hart IR, et al. (2002) BAG-I expression in human breast cancer: interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data. J Pathol 197(1):51-59
11. Nadler Y, Camp RL, Giltnane JM, et al. (2008) Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 10(2):R35
12. Tang SC (2002) BAG-1, an anti-apoptotic tumour marker. IUBMB Life 53(2):99-105
13. Millar EK, Anderson LR, McNeil CM, et al. (2009) BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer 100(1):123-133
14. Gee JM, Aleskandarany MA, Finlay P et al. (2010) Immunohistochemical markers progesterone, HER2, Ki67 and Bcl-2-associated anthogene 1 and prediction of adjuvant tamoxifen treatment outcome in ER+ early breast cancer In: San Antonio breast cancer symposium, San Antonio
15. Barton S, Zabaglo L, A'Hern R, et al. (2012) Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer 106(11):1760-1765
16. Harper-Wynne CL, Sacks NP, Shenton K, et al. (2002) Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20(4):1026-1035
17. Petry IB, Fieber E, Schmidt M, et al. (2010) ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. Clin Cancer Res 16(2):451-460
18. Cutress RI, Townsend PA, Sharp A, et al. (2003) The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. Oncogene 22(32):4973-4982